Stargardt Disease Pipeline Advances as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's "Stargardt Disease Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight's comprehensive Stargardt Disease Pipeline Report @ Stargardt Disease Pipeline Insight- https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Stargardt Disease Pipeline Report

• DelveInsight's Stargardt Disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
• The leading Stargardt Disease Companies such as Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
• Promising Stargardt Disease Pipeline Therapies such as Tinlarebant, OCU410ST, ALK-001, ASP-7317, SGT-1001, ABCA4, NSR-ABCA4, SB-007, and others.
• Among the companies developing Stargardt Disease drugs, Belite Bio has its drug candidate in the most advanced stage - Phase III.

Stay informed about the cutting-edge advancements in Stargardt Disease treatments @ Stargardt Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

The Stargardt Disease Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Stargardt Disease Pipeline Report also highlights the unmet needs with respect to Stargardt Disease.

Stargardt Disease Overview

Stargardt disease, stemming from a hereditary anomaly in the ABCA4 gene, manifests when both copies of this gene, one from each parent, carry mutations. This genetic defect leads to the accumulation of lipofuscin, a metabolic waste product, within the retina. Normally, the retina efficiently clears away this material, but in Stargardt disease, this clearance process is hindered, resulting in damage to retinal cells and subsequent vision loss. The severity of the condition varies widely among individuals due to the diverse spectrum of mutations within the ABCA4 gene.

Stargardt disease presents a range of symptoms, primarily affecting central vision, with manifestations such as blurry, distorted, or dark areas, owing to damage in the macula, which is critical for detailed central vision. Color perception and light adjustment may also be compromised. Diagnosis typically involves a thorough eye examination to detect characteristic yellowish lipofuscin deposits in and around the macula, complemented by tests like fluorescein angiography and genetic analysis to pinpoint the specific genetic mutation. A definitive cure for Stargardt disease remains elusive, though ongoing research explores various avenues such as gene therapy, nanoparticle interventions, anti-sense oligonucleotides, pharmaceutical approaches, dietary supplements, and cell replacement therapy.

Explore More Insights into the Report @ Stargardt Disease Treatment Market Size- https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Stargardt Disease Emerging Drugs Profile

• Tinlarebant: Belite Bio
Tinlarebant is a novel oral therapy intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol-binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the US, Europe, and Japan for the treatment of STGD1. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Stargardt disease.

• KIO-301: Kiora Pharmaceuticals
KIO-301 is a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). It targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. Unlike healthy eyes where photoreceptors perform light detection, KIO-301 selectively enters RGCs downstream of degenerated photoreceptors. Inside RGCs, it interacts with voltage-gated ion channels. When exposed to light, KIO-301 changes shape, altering current flow and activating neurons to signal the brain; removal of light causes KIO-301 to revert to its original shape, halting signaling. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of Stargardt disease.

• OCU410: Ocugen
OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role in in-vitro and in-vivo (animal model) studies. These results demonstrate the ability of OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA. Currently, the drug is in the Phase I/II stage of its clinical trial for the treatment of Stargardt disease.

For More Information on the Report @ Stargardt Disease Prevalence- https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

The Stargardt Disease Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Stargardt Disease, with aggregate therapies developed by each company.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stargardt Disease treatment.
• Stargardt Disease Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.
• Stargardt Disease Drugs under development, based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements, and financing details for future advancement of the Stargardt Disease market.

Stargardt Disease Companies

Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.

Stargardt Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Stargardt Disease Products have been categorized under various Molecule types such as:
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Stargardt Disease treatment by visiting our website @ Stargardt Disease Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Scope of the Stargardt Disease Pipeline Report

• Coverage - Global
• Stargardt Disease Companies - Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
• Stargardt Disease Pipeline Therapies - Tinlarebant, OCU410ST, ALK-001, ASP-7317, SGT-1001, ABCA4, NSR-ABCA4, SB-007, and others.
• Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of the Stargardt Disease Pipeline on our website, @ Stargardt Disease Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Table of Contents

• Introduction
• Executive Summary
• Stargardt Disease: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Stargardt Disease - DelveInsight's Analytical Perspective
• Late Stage Products (Phase III)
• Mid Stage Products (Phase II)
• Early Stage Products (Phase I)
• Preclinical and Discovery Stage Products
• Inactive Products
• Stargardt Disease Key Companies
• Stargardt Disease Key Products
• Stargardt Disease - Unmet Needs
• Stargardt Disease - Market Drivers and Barriers
• Stargardt Disease - Future Perspectives and Conclusion
• Stargardt Disease Analyst Views
• Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.